Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients will be men or women, between 18 and 75 years old.~* Patients must have been taken an stable dosis of Angiotensine Converter Enzyme Inhibitor, Angiotensine Receptor Antagonism or antialdosterone at last 6 months before screening visit.~* Patients should not be on dialysis treatment.~* Women should not be pregnant, or in fertile period (at last 1 year postmenopausal or chirurgic sterilized or using this contraceptive methods: condoms, gel, intrauterine devices, anticonceptives, etc. During at last 3 months after the study beginning.~Exclusion Criteria:~* Patients have taken active vitamin D during 6 months after the screening.~* Patients with allergy o sensibility to paricalcitol.~* Patients with acute CKD 12 weeks before the screening.~* Patients with chronical gastrointestinal disease.~* Patients with hypo or hyperthyroidism.~* Patients with secondary hypertension~* Bad controled hypertension patients~* Patients with renal lithiasis~* Patients with drug dependence~* Patients taking calcitonins, biphosphonates, cinacalcet or others Ca-metabolism drugs.~* Patients taking immunosuppressor drugs.~* Patients not adequate to study as medical opinion.~* HIV patients~* Seric P \> 5.0 mg/dl.~* Seric Ca\> 10,0 mg/dl.~* Proteinuria \> 3.500 mg/g~* Hypoalbuminemia \< 3g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol, Daily treatment, CKD (Type: EXPERIMENTAL): Experimental Arm
- Daily treatment for CKD (Type: OTHER): Comparator Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).